Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Ampronix
Schiller

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

By Medimaging International staff writers
Posted on 23 Apr 2014
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).
Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.

The interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial was published online March 17, 2014, in the Journal of Clinical Oncology. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these preliminary findings are upheld over time.

Dr. J.M.M. Raemaekers, from the Radboud University Medical Center (Nijmegen, The Netherlands), and central coordinator of the study stated, “The standard treatment for patients with clinical stage I/II Hodgkin’s lymphoma is ABVD [adriamycin, bleomycin, vinblastin and dacarbazin] chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate.”

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin’s lymphoma who had a negative early PET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1,137 patients with untreated clinical stage I/II Hodgkin’s lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative early PET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

One progression occurred in the standard arm and nine progressions occurred in the research arm, for patients with a favorable prognosis and a negative early PET scan. For patients with unfavorable prognosis and a negative early PET scan, seven events occurred in the standard arm and 16 events occurred in the research arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show noninferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for early PET-negative patients.
The study was closed for recruitment in June 2011 with a total of 1952 patients. The intergroup EORTC 20051 H10 trial is coordinated by the EORTC Lymphoma Group in collaboration with the LYmphoma Study Association (LYSA) and the Fondazione Italiana Linfomi (FIL). It is being conducted in 159 sites in eight countries: Belgium, Croatia, Denmark, France, Italy, Slovakia, Switzerland, and The Netherlands.

Related Links:

Radboud University Medical Center



ARAB HEALTH
PCI Precision Charts
Supersonic Imagine

Channels

Radiography

view channel
Image: This shows a 3D print model used in surgical planning (Photo courtyes of RSNA).

3D Printing and CT Imaging Used to Guide Human Face Transplants

Surgeons are using computed tomography (CT) imaging and three-dimensional (3-D) printing technology to reconstruct life-size models of patients’ heads to help better control the outcome in face transplantation... Read more

MRI

view channel
Image: Head impact telemetry system (HITs) helmet-mounted accelerometers are used in youth and collegiate football to evaluate the frequency and severity of helmet impacts (Photo courtesy of RSNA).

DTI-MRI Shows Brain Alterations in High School Football Players After Only One Season

Some high school football players exhibit measurable brain alterations after only one season of play, even in the absence of concussion. The new findings were presented at the annual meeting of the... Read more

General/Advanced Imaging

view channel
Image: The DermSpectra total body digital skin imaging system (Photo courtesy of DermSpectra).

Total Body Digital Skin Imaging System Developed for Dermatology and Primary Care Practices

A total body digital skin imaging system enables physicians to track critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) in their office, over time. The DermSpectra (Tucson,... Read more

Imaging IT

view channel
Image: The DCMSYS Interface WebBridge is designed to connect to DCMSYS product range to access all the patient data, search studies, link data to the appropriate study and store, modify, share, and connect to any repository (Photo courtesy of Dicom Systems).

WebBridge Software for Medical Facilities Allows Third-Party Interfaces to Develop Front-End Functionality in a Matter of Days

Designed for medical facilities of any size, new web software allows any native or web-based third-party application to upload any non-standard data (e.g., JPEG, TFF, PDF, TXT, etc.) to an enterprise imaging... Read more

Industry News

view channel

X-Ray and Digital X-Ray Sector Nears USD 8 Billion in 2014

The market for both traditional and digital X-ray systems is estimated to reach USD 7.9 billion in 2014, according to a recent report from an international market research company. The healthcare market research publisher noted that upgrades of existing equipment and the rising incidence of disease are fueling the market.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.